Introduction {#Sec1}
============

Radiation-induced brain necrosis (RN) is a serious complication caused by radiation therapy. Occurrence of RN can be acute, sub-acute, and delayed, which adversely worsens neurologic functions and impairs the quality of life of recipients. Corticosteroids are commonly used as a protective agent for RN. However they have significant side effects depending on the dose and duration of exposure. Side effects can include diabetes, iatrogenic Cushing syndrome, myopathy, avascular necrosis, psycho-mood disturbance, etc. \[[@CR1]\]. Although corticosteroids may ameliorate the severity of the signs and symptoms related to RN, the effect may lost once the steroids are discontinued \[[@CR2]\]. Alternative therapies such as hyperbaric oxygen therapy, antiplatelet agents, anticoagulants, and/or vitamins have clinically been tested but the outcomes are disappointing. Antiangiogenic agent, bevacizumab has recently been reported to be promising \[[@CR3], [@CR4]\], yet with flaw of potential toxicity and high cost. Surgical debulk is one of the treatment options but many RN lesions are inoperable because of the location, or the fact that patients may be medically illegible for surgery \[[@CR5]--[@CR7]\].

The pathogenesis of RN is under exploration but not fully understood. It has been confirmed that chronic oxidative stress and inflammatory reaction play key roles in the pathogenesis of radiation-induced late normal tissue injury \[[@CR8], [@CR9]\]. Free radicals can be generated directly or indirectly by ionizing radiation \[[@CR10], [@CR11]\]. Ample evidence from laboratory experiments revealed that excessive generation of free radicals causes tissue damage in many ways by which they react on protein, lipid, and double DNA strands resulting in metabolic disturbances and cellular death. Specifically, the central nervous system (CNS) is vulnerable to oxidative stress, therefore, eliminating the insulting effects induced by free radicals, may be beneficial in alleviation of cellular damage.

Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), as an effective free radical scavenger \[[@CR12]--[@CR15]\], has been used in treating a wide range of oxidative stress-related diseases, including cerebral ischemia, by scavenging free radicals and suppressing the inflammatory reactions \[[@CR16]\]. However, whether edaravone has a therapeutic effect on RN is unknown. To test this hypothesis, we carried out a prospective randomized open-labeled clinical study on the effect of edaravone on RN.

Methods {#Sec2}
=======

This prospective study was a 3-month, open-labeled clinical trial on RN comparing the patients treated with edaravone plus corticosteroid to control group treated with corticosteroid alone. The study was performed at the Department of Neurology of Sun Yat-Sen Memorial hospital, Sun Yat-Sen University, and was approved by the authorized human research review board in our institutes in accordance with the Helsinki declaration. Written informed consents were obtained from all participants.

Participants {#Sec3}
------------

Patients were enrolled between March 2009 and September 2012. The inclusion criteria were as follows: ①Have received radiotherapy for histologically confirmed nasopharyngeal carcinoma; ②Radiotherapy was finished ≥6 months prior to study entry; ③Radiographic evidence to support the diagnosis of RN without tumor recurrence \[[@CR17]\]; ④Age ≥ 18 years; ⑤No evidence of increased intracranial pressure suggestive of a brain herniation; ⑥Routine laboratory studies with bilirubin ≤2\*upper limits of normal (ULN), aspartate aminotransferase (AST or SGOT) \<2\* ULN, creatinine \<1.5\*ULN, red-cell count ≥4,000 per cubic millimeter; white-cell count ≥1500 per cubic millimeter, platelets ≥75,000 per cubic millimeter; Hb ≥ 90 g/L, prothrombin time(PT), activated partial thromboplastin time(APTT), international normalized ratio(INR) in a normal range; ⑦Being able to understand and willing to sign a written informed consent document. Considering the potential side effects of edaravone on liver function, after the trial was started, we decided to enroll patients with normal AST. The exclusion criteria were as follows: ①Evidence of tumor recurrence or metastases; ②Other CNS disorders, such as cerebral vascular events, inflammatory and neurodegenerative diseases; ③Concomitant significant systemic diseases such as cardiovascular diseases; ④History of anaphylactic response to edaravone. All participants have received radical radiotherapy using a conventional two-dimensional radiotherapy technique.

Interventions {#Sec4}
-------------

Participants were randomized in the ratio of 1:1 into the control group and the edaravone group. All participants received a conventional corticosteroid regimen (administration of daily intravenous methylprednisolone 500 mg for 3 consecutive days followed by oral prednisolone tapering down to off in 30 days. Edaravone was given at 30 mg, twice per day for 14 days as a reference of the dosage used in patients with ischemic stroke \[[@CR18]\]. Demographic data, total dose (Gy), diagnosis, treatments, clinical and radiographic responses of participants were collected.

Outcomes {#Sec5}
--------

Clinical symptoms and signs were evaluated by Late Effects of Normal Tissues --Subjective, Objective, Management, Analytic (LENT/SOMA) scale \[[@CR19]\] before entry of the trial and 3 months after treatment. Subjective domain contains five items: headache, somnolence, intellectual deficit, functional competence, and memory. Objective domain contains four items: neurologic deficit, cognitive functions, mood & personality changes, and seizures. Analytic domain includes neuropsychologic and radiological assessments. Each parameter scores from 1 to 4, score 0 if there are no toxicities. The total of each parameter represents the final score of the LENT/SOMA scale \[[@CR19]\]. The radiological response was assessed by MRI difference between pretreatment and post-treatment, which included T~1~-weighted gadolinium contrast-enhanced and T~2~-weighted image. The edge of the maximum area of each lesion was draw by the manual approach and calculated automatically by software Volume Viewer 2(GE, AW Suite 2.0, 6.5.1.z). MRI studies were evaluated by two neuroradiologists who were blinded to the grouping.

The primary endpoint was the proportion of the edema reduction in area at 3 months. A reduction in edema area of ≥25 % constituted a response, which was estimated on T~2~-weighted images. The LENT/SOMA scale score was selected as the secondary endpoint measures.

Statistical analysis {#Sec6}
--------------------

We designed the present study with an α of 0.05, and power of 90 %. In order to detect an increase of 30 % in response rate between the two arms, the estimated sample size for this study was 112 patients (56 patients in each arm). The data were expressed as mean ± standard deviation (SD). T test was used to compare age, radiation dose, latency of RN between the edaravone group and the control group. LENT/SOMA scale scores between the two groups were assessed by Mann--Whitney*U* Test. The χ^2^ test was used to analyze the therapeutic efficacy. Differences in the T~1~-weighted gadolinium enhancement and T~2~-weighted image between the two groups were also evaluated by *t* test. A *p* value of less than 0.05 was accepted as significant.

Results {#Sec7}
=======

Demographic data {#Sec8}
----------------

Between March 2009 and September 2012, a total of 162 patients were added to the study. Of these, 154 who fulfilled the inclusion criteria were enrolled in the study. Seventy-seven were enrolled in the edaravone-treated group and another 77 in the control group. During the study, 17 (5 in edeverone group and 12 in control group) withdrew. In control group, one patient suffered from severe pulmonary infection and could not continue the corticosteroid therapy. Five patents in the control group asked for edaravone, therefore also withdrew from the protocol. A total of 11 patients were lost to follow-up. The final number of the subjects in the study was 137, namely 72 in edavarone group and 65 in control group, as shown in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Flow diagram of our study

All participants received radiotherapy at a total dose of 68--82 Gy (2 Gy/fraction, 5 fractions per week). The patients' age ranged from 25 to 80 years old, with an average of 50.6 ± 10 years. The latency from radiotherapy to diagnosis of RN was 5.4 ± 4.2 years. The most frequent symptoms were headache, dizziness, fatigue, dysphasia, hearing loss, memory decline, personality change, and seizures. Twenty-seven patients (19.7 %) had clinical evidence of cranial nerve palsy. Clinical data of the two groups are summarized in Table [1](#Tab1){ref-type="table"}. There were no statistical differences between the two groups regarding age, gender, latency of RN, total radiation dose, scores of LENT/SOMA scale at baseline, and maximum area of necrosis lesions.Table 1Baseline characteristics of the study populationEdaravone group\
(*n* = 72)Control group (*n* = 65)*p* valueAge (year)49.2 ± 9.252.0 ± 11.00.099Gender Male56520.835 Female1613Primary tumorNPCNPC1.000Cranial nerve palsy14131.000Latency of RN (year)5.6 ± 4.65.1 ± 3.70.508Conventional RT (Gy)72.6 ± 3.171.4 ± 3.30.052LENT/SOMA scores 654510.558 71413 841T~1~-weight gadolinium-contrast area (cm^2^)6.77 ± 5.097.68 ± 4.770.286T~2~-weithted area (cm^2^)19.42 ± 10.5422.58 ± 10.090.075*NPC* nasopharyngeal carcinoma, *RN* radiation-induced brain necrosis, *RT* radiotherapy

MRI observations {#Sec9}
----------------

MRI scan was obtained at the baseline prior to the entry of the trial and 3 months after completing the trial. Forty patients in edaravone group and twenty-three patients in control group exhibited radiological improvement (55.6 vs. 35.4 %, *p* = 0.025). Though both two groups showed significantly decreased edema area measured in T~2~-weighted MRI (edaravone group 5.08 ± 10.32 cm^2^, *p* = 0.000; control group 2.05 ± 6.71 cm^2^, *p* = 0.016), more reduced edema area was demonstrated in edaravone group compared with that in the control group (*p* = 0.042). Notably, patients in both groups showed a significant decrease in the size of the T~1~-weighted gadolinium enhancement (edaravone group, 1.67 ± 4.69 cm^2^, *p* = 0.004; control group, 1.20 ± 2.71 cm^2^, *p* = 0.001, Table [2](#Tab2){ref-type="table"}), but it did not reach the statistical difference between the two groups (*p* = 0.468, Table [2](#Tab2){ref-type="table"}). Figure [2](#Fig2){ref-type="fig"} showed a representative images obtained in a patient with edaravone.Table 2Efficacy of Improvement Evaluated by LENT/SOMA scale and MRIEdaravone group\
(*n* = 72) (%)Control group\
(*n* = 65) (%)*p* valueLENT/SOMA Improved44 (61.1)25 (38.5)0.006 Ineffective28 (38.9)40 (61.5)MRI Reduction in T~1~ + C (cm^2^)1.67 ± 4.691.20 ± 2.710.468 Reduction in T~2~ (cm^2^)5.08 ± 10.322.05 ± 6.710.042*T* ~*1*~ *+* *C* T~1~-weighted gadolinium contrast enhancementFig. 2MRI of one patient in edaravone group. **a**, **b** showed *left* temporal lobe necrosis (*arrow head*) before treatment. Three months after treatment, T~2~-weighted edema (**c**) and T~1~-weighted gadolinium contrast-enhancement (**d**) were significantly reduced

LENT/SOMA scale results {#Sec10}
-----------------------

LENT/SOMA scale was evaluated before treatment and 3 months after treatment. A reduction in score of the LENT/SOMA scale of ≥1 constituted an improvement. Forty-four in the edaravone group and 25 control group patients showed clinical improvement, from which a significantly better response was observed in edaravone group than that of the control group (61.1 vs. 38.5 %, *p* = 0.006, Table [2](#Tab2){ref-type="table"}).

Adverse events {#Sec11}
--------------

The adverse events are listed in Table [3](#Tab3){ref-type="table"}. Nine of 72 patients in edaravone group and 10 of 65 in the control group had adverse events, without significant difference between two groups. Of these 19 events, none of them were serious: seven were insomnia, six high blood glucose, three epistaxis, two mild dysfunction of liver and one hypertension.Table 3Adverse events in the two groupsEdaravone group\
(*n* = 72) (%)Control group\
(*n* = 65) (%)*p* valueEpistaxis1 (1.4)2 (3.1)0.604High blood glucose3 (4.2)3 (4.6)1.000Dysfunction of liver\*2 (2.7)0 (0.0)0.498Hypertension0 (0.0)1 (1.5)0.474Insomnia3 (4.2)4 (6.2)0.708**\*** Dysfunction of liver was defined as aspartate aminotransferase or alanine aminotranferase \>/= 2 \* upper limits of normal

Discussion {#Sec12}
==========

RN is a serious complication of radiotherapy. It may cause significant focal dysfunction and/or cognitive impairment. The incidence of RN was reported to be 4.6 % in 10 years to 35 % in 3.5 years after radiotherapy \[[@CR20]\]. Although corticosteroid is employed as the major conventional therapeutic agent for RN, its efficacy remains unsatisfactory \[[@CR21]\].

Previous studies have shown that the free radical scavenger, edaravone, bears neuroprotective effect in some oxidative stress-related diseases \[[@CR16], [@CR22], [@CR23]\]. The amenable mechanism of edaravone in this regard is believed to suppress the production of free radicals and scavenge reactive oxidative species in the brain \[[@CR24]\]. This anti-oxidative property protects cellular structures from oxidative injury and cell death because oxidative stress has been confirmed in mediating radiation-induced injury \[[@CR25]\]. It may also prevent the neural precursor cells from apoptosis in the neurogenesis zone of the brain \[[@CR26], [@CR27]\]. In addition, edaravone inhibits the expression of vascular endothelium growth factor in astrocytes \[[@CR28]\], and has been shown to protect neurons from cell death after irradiation \[[@CR27]\]. These observations suggest that edaravone may have a protective effect on the brain from development of RN.

In our study, patients in both edaravone and control groups exhibited a significant reduction in T~1~-weighted contrast enhancement and T~2~-weighted edema. Moreover, edaravone-treated patients have a significantly reduced edema area compared with that of patients from control group, indicating that adding edaravone to corticosteroid regimen can enhance radiological improvement relevant to RN. Although no statistical significance was observed in T~1~-weighted image between the two groups in our study, it may be due to the small size of the samples. Our results also demonstrated that clinical symptoms did not always parallel with the MR imaging. Some patients might have symptoms virtually gone without significant recovery of necrosis lesions.

Several therapeutic agents adjunct to the conventional corticosteroid regimen have been tested for RN in the past two decades (e.g. anticoagulants, anti-platelets, hyperbaric oxygen therapy), but their use is not widely accepted because of the potential adverse effects and limited randomized control trials. Since radiotherapy on head and neck may cause carotid stenosis \[[@CR29]\], intracranial hemorrhage or epistaxia, the therapeutic agent adjunct to corticosteroid must be safe from leading to ischemic or hemorrhagic events. Edaravone has been reported to be effective in ischemic stroke and aneurismal subarachnoid hemorrhage \[[@CR23]\], it may be safe in RN too. In our study, the fact that no fatal or severe adverse events were observed in the edaravone group supported our notion.

In conclusion, our results suggested that administration of edaravone adjunct to the conventional corticosteroid regimen may be beneficial in reduction of RN. To validate the neuroprotective effect of edaravone, a large scale study is warranted, and the long term effect of edaravone therapy should be elucidated. In addition, the edaravone-treated patients needed additional charges for the drug, although they had a better clinical outcome. Thus, cost-benefit analysis is also recommended for its further usage.
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